CervoMed (CRVO) 8-K/A Financial Statements and Exhibits

Exhibit 99.2

The following pro forma financial information has been prepared as if the Merger between RestorGenex and the Company occurred on March 31, 2014 for the Pro Forma Statement of Income for the Three Months Ended March 31, 2014.

The information in these pro forma financials for the Company has been derived from the unaudited financial statements for the three months ended March 31, 2014. The information in these pro forma financials for RestorGenex has been derived from the unaudited financial statements for the three months ended March 31, 2014.Need to make sure the numbers tie to current financials.

RestorGenex Corporation and Paloma Pharmaceuticals, Inc.

Pro Forma Income Statements

For the Three Months Ended March 31, 2014

	Three Months Ended March 31, 2014 (a)
										Pro Forma			Pro Forma
	RestorGenex			Paloma			VasculoMedics			Adjustments			Combined
Revenues	$	–			–		$	–		$	–		$	–
Cost of revenues		–			–			–			–			–
Gross profit		–			–			–			–			–
Operating expenses
General, administrative, research and development		611,845			102,153			–			81,250	(b)		795,248
Warrants, options and stock		149,885						–			–			149,885
Legal and professional services		131,686			1,725			–			–			133,411
Depreciation and amortization		478,104			634			–			27,755	(c)		506,493
Total operating expenses		1,371,520			104,512			–			109,005			1,585,037
Loss from operations		(1,371,520	)		(104,512	)		–			(109,005	)		(1,585,037	)
Other (income)/expenses
Other (income)/expenses		(49,639	)		(25,397	)		–			–			(75,036	)
Interest expense		58,294			29,925						–			88,219
Total other (income)/expenses		8,655			4,528			–			–			13,183
Net loss from continuing operations		(1,380,175	)		(109,040	)		–			(109,005	)		(1,598,220	)
Net loss from discontinued operations		–			–			–			–			–
Net loss	$	(1,380,175	)	$	(109,040	)	$	–		$	(109,005	)	$	(1,598,220	)
Basic and diluted earnings per share	$	(0.23	)										$	(0.18	)
Basic and fully-diluted weighted average shares outstanding		5,934,474			2,500,000	(d)		220,000	(d)					8,654,474

(a)	Assumes the mergers with Paloma and VasculoMedics occurred on January 1, 2014.
(b)	Impact of employment agreement from January 1, 2014 to March 31, 2014.
(c)	Amortization of intangible assets for Paloma assuming a 20-year amortization period.
(d)	Impact on weighted average shares outstanding for the acquisition shares being outstanding for the entire quarter.

1